• Mutation; VGNC; 42508; KRAS; Simple; p.Glu63Lys (c.187G>A); Zygosity=Heterozygous (PubMed=31175136).
  

PubMed=19147538; DOI=10.1158/1541-7786.MCR-08-0347
Zhang J., Chen X., Kent M.S., Rodriguez C.O., Chen X.-B.
Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor.
Mol. Cancer Res. 7:67-78(2009)

PubMed=21552385; DOI=10.7150/jca.2.262
Legare M.E., Bush J., Ashley A.K., Kato T., Hanneman W.H.
Cellular and phenotypic characterization of canine osteosarcoma cell lines.
J. Cancer 2:262-270(2011)

PubMed=21801068; DOI=10.2460/ajvr.72.8.1097
Stokol T., Daddona J.L., Mubayed L.S., Trimpert J., Kang S.
Evaluation of tissue factor expression in canine tumor cells.
Am. J. Vet. Res. 72:1097-1106(2011)

PubMed=21908323; DOI=10.1177/1040638711408064
O'Donoghue L.E., Rivest J.P., Duval D.L.
Polymerase chain reaction-based species verification and microsatellite analysis for canine cell line validation.
J. Vet. Diagn. Invest. 23:780-785(2011)

PubMed=22849686; DOI=10.2460/ajvr.73.8.1252
Urbasic A.S., Hynes S., Somrak A.J., Contakos S., Rahman M.M., Liu J., MacNeill A.L.
Oncolysis of canine tumor cells by myxoma virus lacking the serp2 gene.
Am. J. Vet. Res. 73:1252-1261(2012)

PubMed=22916246; DOI=10.1371/journal.pone.0043355
Maeda J., Yurkon C.R., Fujisawa H., Kaneko M., Genet S.C., Roybal E.J., Rota G.W., Saffer E.R., Rose B.J., Hanneman W.H., Thamm D.H., Kato T.A.
Genomic instability and telomere fusion of canine osteosarcoma cells.
PLoS ONE 7:E43355-E43355(2012)

PubMed=23365669; DOI=10.1371/journal.pone.0054464
Wells J.W., Evans C.H., Scott M.C., Rutgen B.C., O'Brien T.D., Modiano J.F., Cvetkovic G., Tepic S.
Arginase treatment prevents the recovery of canine lymphoma and osteosarcoma cells resistant to the toxic effects of prolonged arginine deprivation.
PLoS ONE 8:E54464-E54464(2013)

PubMed=25190452; DOI=10.1186/s12917-014-0184-9
Pang L.Y., Argyle S.A., Kamida A., Morrison K.O., Argyle D.J.
The long-acting COX-2 inhibitor mavacoxib (Trocoxil TM) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro.
BMC Vet. Res. 10:184.1-184.11(2014)

PubMed=27257868; DOI=10.1371/journal.pone.0156689
Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.
Intrinsic radiosensitivity and cellular characterization of 27 canine cancer cell lines.
PLoS ONE 11:E0156689-E0156689(2016)

PubMed=26842912; DOI=10.1111/vco.12197
Hartley G., Faulhaber E., Caldwell A., Coy J., Kurihara J., Guth A., Regan D.P., Dow S.W.
Immune regulation of canine tumour and macrophage PD-L1 expression.
Vet. Comp. Oncol. 15:534-549(2017)

PubMed=27197945; DOI=10.1111/vco.12192
Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.
The Flint Animal Cancer Center (FACC) canine tumour cell line panel: a resource for veterinary drug discovery, comparative oncology and translational medicine.
Vet. Comp. Oncol. 15:481-492(2017)

PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346
Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.
Identifying candidate druggable targets in canine cancer cell lines using whole exome sequencing.
Mol. Cancer Ther. 18:1460-1471(2019)

PubMed=33126659; DOI=10.3390/ani10111981
Modesto P., Fernandez J.L.C., Martini I., Zoccola R., Pugliano M.C., De Ciucis C.G., Goria M., Ferrari A., Razzuoli E.
Characterization of D-17 canine osteosarcoma cell line and evaluation of its ability to response to infective stressor used as alternative anticancer therapy.
Animals 10:1981.1-1981.16(2020)

PubMed=34079834; DOI=10.3389/fvets.2021.666838
Gola C., Giannuzzi D., Rinaldi A., Iussich S., Modesto P., Morello E., Buracco P., Aresu L., De Maria R.
Genomic and transcriptomic characterization of canine osteosarcoma cell lines: a valuable resource in translational medicine.
Front. Vet. Sci. 8:666838.1-666838.11(2021)